Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 5/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182840 | 0.82 | CSF1R (0.42) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL127954 | 0.81 | PDE4A (0.45) | CSF1R | |
| SCHEMBL129404 | 0.81 | PDE4D (0.41) | LPLLIPGBACE1 | |
| SCHEMBL15969023 | 0.80 | CSF1R (0.42) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL15968637 | 0.80 | LPL (0.38) | LPLLIPGBACE1SYKCA1 | |
| SCHEMBL15320232 | 0.79 | RORC (0.44) | GRM2LPLLIPGBACE1CA1 | |
| SCHEMBL30717778 | 0.79 | RORC (0.44) | GRM2LPLLIPGBACE1CA1 | |
| SCHEMBL16695355 | 0.79 | LPL (0.37) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL23242451 | 0.78 | LPL (0.41) | LPLLIPGBACE1F2F11 | |
| SCHEMBL21434075 | 0.78 | LPL (0.41) | LPLLIPGF2F11PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2963043-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014133022-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | GRM2, GRM1, GRIA2 | GRM2 1/4885LPL 4001/4885LIPG 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.